Figure 3 | Scientific Reports

Figure 3

From: Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Figure 3Figure 3

(A) Distribution of change in LMW-F between V1 and V4 16 weeks apart and after 6-weeks fenofibrate. (B) LMW-F levels before and after 6-weeks fenofibrate (p < 0.001). ( C) Changes in LMW-F levels over time and with fenofibrate in participants with LMW-F measurements at V7. All participants received fenofibrate from V1 to V4 (for the last 6 weeks), before being subsequently randomised to 5 years of fenofibrate or placebo. Error bars show 95% CIs.

Back to article page